Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Designed SARS‐CoV‐2 receptor binding domain variants form stable monomers

25 Jan 2022

Abstract excerpt

The receptor binding domain (RBD) of the SARS-CoV-2 spike (S)-protein is a prime target of virus-neutralizing antibodies present in convalescent sera of COVID-19 patients and thus is considered a key antigen for immunosurveillance studies and vaccine development. Although recombinant expression of RBD has been achieved in several eukaryotic systems, mammalian cells have proven particularly useful. The authors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SARS-CoV-2 and COVID-19 Research
Share to COVID-19 Clinical Research Studies
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35078277
DOI: 10.1002/biot.202100422

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Designed SARS‐CoV‐2 receptor binding domain variants form stable monomersPMID 35078277Read ↗

Spike Proteins of SARS –CoV-2: a detailed perspective on structure, receptor binding, antigenicity, vaccine development and neutralizationSemantic proximity Read ↗

Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse ModelSemantic proximity Read ↗

Incorporation of Sars-Cov-2 Spike Ntd to Rbd-Based Vaccine Improves Immunity and Protection Against Viral VariantsSemantic proximity Read ↗

Genetic Modification to Design a Stable Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain as a COVID-19 Vaccine CandidateSemantic proximity Read ↗

The Nuts and Bolts of SARS-CoV-2 Spike Receptor-Binding Domain Heterologous ExpressionSemantic proximity Read ↗

Recombinant SARS-CoV-2 spike proteins for sero-surveillance and epitope mappingSemantic proximity Read ↗

Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variantsSemantic proximity Read ↗

Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain, RBD203-N1 as a COVID-19 Protein Vaccine CandidateSemantic proximity Read ↗

Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variantsSemantic proximity Read ↗

Stabilizing the closed SARS-CoV-2 spike trimer.Semantic proximity Read ↗

Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through OmicronSemantic proximity Read ↗

Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.